The cardiac marker market size has grown rapidly in recent years. It will grow from $12.38 billion in 2025 to $13.95 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to increasing burden of cardiovascular diseases, expansion of hospital laboratory infrastructure, rising use of emergency cardiac testing, growing reliance on biomarker-based diagnosis, improvements in assay sensitivity.
The cardiac marker market size is expected to see rapid growth in the next few years. It will grow to $22.7 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing demand for faster turnaround diagnostic tests, rising integration of cardiac diagnostics with digital platforms, expansion of point-of-care testing facilities, growing adoption of advanced biomarker panels, increasing focus on precision cardiology. Major trends in the forecast period include increasing use of high-specificity cardiac marker panels, rising adoption of automated immunoassay systems, growing demand for rapid cardiac diagnosis, expansion of multiparametric testing approaches, enhanced focus on clinical decision support.
The projected surge in the cardiac marker market is strongly driven by the escalating prevalence of cardiac diseases. This category comprises conditions affecting the heart's structure or functionality, leading to a spectrum of medical issues. Cardiac markers serve as crucial tools in diagnosing and monitoring various heart-related conditions such as heart attacks, angina, heart failure, and other cardiovascular diseases. Consequently, the demand for diagnostic tests involving cardiac markers has seen a notable increase. For instance, the British Heart Foundation reported an alarming increase of 30,000 deaths from coronary heart disease in England from the pandemic's onset to August 2022. Moreover, a staggering 346,000 individuals were on cardiac waiting lists by August 2022. Hence, the escalating prevalence of cardiac diseases significantly fuels the growth of the cardiac marker market.
Leading companies in the cardiac marker market prioritize innovative products, such as high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers, to drive market revenue. These biomarkers play crucial roles in diagnosing, categorizing, and treating cardiovascular ailments. For instance, in October 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a prominent China-based medical equipment and solutions provider, launched troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The hs-cTn assay surpasses minimal sensitivity, accuracy, and reliability requirements, aiding in identifying myocardial damage. These advanced products aim to enhance treatment approaches for cardiovascular diseases, offering dependable solutions to improve patient outcomes in both cardiovascular and related health contexts.
In April 2023, Abbott Laboratories, a US-based healthcare company acquired Cardiovascular Systems Inc. for an undisclosed amount. With this acquisition, Abbott will be able to better serve patients with peripheral and coronary artery disease by offering a novel and cutting-edge therapy for those with complicated cardiovascular disease. Through this acquisition, Abbott is able to expand the range of cutting-edge vascular devices it offers doctors, giving them more resources to assist patients. Cardiovascular Systems Inc. a US-based medical technology company.
Major companies operating in the cardiac marker market are Abbott Laboratories, F Hoffmann-La Roche AG, Siemens Healthineers AG, Danaher Corporation, Thermo Fisher Scientific Inc, bioMérieux SA, Bio-Rad Laboratories Inc, Beckman Coulter Inc, QuidelOrtho Corporation, Randox Laboratories Ltd, DiaSorin SpA, Tosoh Corporation, PerkinElmer Inc, Sysmex Corporation, Mindray Bio-Medical Electronics Co Ltd, Lepu Medical Technology Beijing Co Ltd, Trinity Biotech plc, Fujirebio Holdings Inc, Euroimmun AG, Abcam plc, Creative Diagnostics.
North America was the largest region in the cardiac marker market in 2025. The regions covered in the cardiac marker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac marker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the cardiac marker market by increasing costs of imported reagents, analytical instruments, chemiluminescence systems, and assay consumables. Hospital labs and reference laboratories in North America and Europe are most affected due to high import dependency, while Asia-Pacific experiences cost pressures on diagnostic manufacturing. These tariffs are increasing per-test costs and slowing system upgrades. However, they are also encouraging domestic production of reagents, local instrument assembly, and development of cost-efficient cardiac testing platforms.
The cardiac marker market research report is one of a series of new reports that provides cardiac marker market statistics, including cardiac marker industry global market size, regional shares, competitors with a cardiac marker market share, detailed cardiac marker market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac marker industry. This cardiac marker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cardiac markers are biomolecules released into the bloodstream in response to heart muscle damage or stress, serving as crucial tools for diagnosing and monitoring a spectrum of cardiac ailments such as heart attacks, angina, and heart failure.
The primary types of cardiac markers encompass troponin, creatine kinase-MB (CK-MB), B-type natriuretic peptide (BNP), myoglobin, and various other biomarkers. Troponin, a protein released upon heart muscle damage, stands as a pivotal marker widely used for diagnosing and monitoring heart-related conditions. Diverse products in the realm of cardiac markers include reagents, instruments, and various detection methodologies such as chemiluminescence, immunofluorescence, immunochromatography, and ELISA. These markers find application across multiple indications, including myocardial infarction, congestive heart failure, acute coronary syndrome, among others. End users encompass laboratory testing facilities, hospital labs, reference labs, contract testing labs, point-of-care testing facilities, and academic institutions, where these markers play a vital role in cardiac diagnostics and monitoring.
The cardiac marker market consists of sales of C-reactive protein (CRP) and Ischemia-modified albumin (IMA). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cardiac marker market size is expected to see rapid growth in the next few years. It will grow to $22.7 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing demand for faster turnaround diagnostic tests, rising integration of cardiac diagnostics with digital platforms, expansion of point-of-care testing facilities, growing adoption of advanced biomarker panels, increasing focus on precision cardiology. Major trends in the forecast period include increasing use of high-specificity cardiac marker panels, rising adoption of automated immunoassay systems, growing demand for rapid cardiac diagnosis, expansion of multiparametric testing approaches, enhanced focus on clinical decision support.
The projected surge in the cardiac marker market is strongly driven by the escalating prevalence of cardiac diseases. This category comprises conditions affecting the heart's structure or functionality, leading to a spectrum of medical issues. Cardiac markers serve as crucial tools in diagnosing and monitoring various heart-related conditions such as heart attacks, angina, heart failure, and other cardiovascular diseases. Consequently, the demand for diagnostic tests involving cardiac markers has seen a notable increase. For instance, the British Heart Foundation reported an alarming increase of 30,000 deaths from coronary heart disease in England from the pandemic's onset to August 2022. Moreover, a staggering 346,000 individuals were on cardiac waiting lists by August 2022. Hence, the escalating prevalence of cardiac diseases significantly fuels the growth of the cardiac marker market.
Leading companies in the cardiac marker market prioritize innovative products, such as high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers, to drive market revenue. These biomarkers play crucial roles in diagnosing, categorizing, and treating cardiovascular ailments. For instance, in October 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a prominent China-based medical equipment and solutions provider, launched troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The hs-cTn assay surpasses minimal sensitivity, accuracy, and reliability requirements, aiding in identifying myocardial damage. These advanced products aim to enhance treatment approaches for cardiovascular diseases, offering dependable solutions to improve patient outcomes in both cardiovascular and related health contexts.
In April 2023, Abbott Laboratories, a US-based healthcare company acquired Cardiovascular Systems Inc. for an undisclosed amount. With this acquisition, Abbott will be able to better serve patients with peripheral and coronary artery disease by offering a novel and cutting-edge therapy for those with complicated cardiovascular disease. Through this acquisition, Abbott is able to expand the range of cutting-edge vascular devices it offers doctors, giving them more resources to assist patients. Cardiovascular Systems Inc. a US-based medical technology company.
Major companies operating in the cardiac marker market are Abbott Laboratories, F Hoffmann-La Roche AG, Siemens Healthineers AG, Danaher Corporation, Thermo Fisher Scientific Inc, bioMérieux SA, Bio-Rad Laboratories Inc, Beckman Coulter Inc, QuidelOrtho Corporation, Randox Laboratories Ltd, DiaSorin SpA, Tosoh Corporation, PerkinElmer Inc, Sysmex Corporation, Mindray Bio-Medical Electronics Co Ltd, Lepu Medical Technology Beijing Co Ltd, Trinity Biotech plc, Fujirebio Holdings Inc, Euroimmun AG, Abcam plc, Creative Diagnostics.
North America was the largest region in the cardiac marker market in 2025. The regions covered in the cardiac marker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac marker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the cardiac marker market by increasing costs of imported reagents, analytical instruments, chemiluminescence systems, and assay consumables. Hospital labs and reference laboratories in North America and Europe are most affected due to high import dependency, while Asia-Pacific experiences cost pressures on diagnostic manufacturing. These tariffs are increasing per-test costs and slowing system upgrades. However, they are also encouraging domestic production of reagents, local instrument assembly, and development of cost-efficient cardiac testing platforms.
The cardiac marker market research report is one of a series of new reports that provides cardiac marker market statistics, including cardiac marker industry global market size, regional shares, competitors with a cardiac marker market share, detailed cardiac marker market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac marker industry. This cardiac marker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cardiac markers are biomolecules released into the bloodstream in response to heart muscle damage or stress, serving as crucial tools for diagnosing and monitoring a spectrum of cardiac ailments such as heart attacks, angina, and heart failure.
The primary types of cardiac markers encompass troponin, creatine kinase-MB (CK-MB), B-type natriuretic peptide (BNP), myoglobin, and various other biomarkers. Troponin, a protein released upon heart muscle damage, stands as a pivotal marker widely used for diagnosing and monitoring heart-related conditions. Diverse products in the realm of cardiac markers include reagents, instruments, and various detection methodologies such as chemiluminescence, immunofluorescence, immunochromatography, and ELISA. These markers find application across multiple indications, including myocardial infarction, congestive heart failure, acute coronary syndrome, among others. End users encompass laboratory testing facilities, hospital labs, reference labs, contract testing labs, point-of-care testing facilities, and academic institutions, where these markers play a vital role in cardiac diagnostics and monitoring.
The cardiac marker market consists of sales of C-reactive protein (CRP) and Ischemia-modified albumin (IMA). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cardiac Marker Market Characteristics
3. Cardiac Marker Market Supply Chain Analysis
4. Global Cardiac Marker Market Trends and Strategies
5. Cardiac Marker Market Analysis of End Use Industries
7. Global Cardiac Marker Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cardiac Marker Total Addressable Market (TAM) Analysis for the Market
9. Cardiac Marker Market Segmentation
10. Cardiac Marker Market Regional and Country Analysis
11. Asia-Pacific Cardiac Marker Market
12. China Cardiac Marker Market
13. India Cardiac Marker Market
14. Japan Cardiac Marker Market
15. Australia Cardiac Marker Market
16. Indonesia Cardiac Marker Market
17. South Korea Cardiac Marker Market
18. Taiwan Cardiac Marker Market
19. South East Asia Cardiac Marker Market
20. Western Europe Cardiac Marker Market
21. UK Cardiac Marker Market
22. Germany Cardiac Marker Market
23. France Cardiac Marker Market
24. Italy Cardiac Marker Market
25. Spain Cardiac Marker Market
26. Eastern Europe Cardiac Marker Market
27. Russia Cardiac Marker Market
28. North America Cardiac Marker Market
29. USA Cardiac Marker Market
30. Canada Cardiac Marker Market
31. South America Cardiac Marker Market
32. Brazil Cardiac Marker Market
33. Middle East Cardiac Marker Market
34. Africa Cardiac Marker Market
36. Cardiac Marker Market Competitive Landscape and Company Profiles
37. Cardiac Marker Market Other Major and Innovative Companies
40. Cardiac Marker Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Cardiac Marker Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cardiac marker market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cardiac marker? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiac marker market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Biomarker: Troponin; Creatine Kinase-MB (CK-MB); B-type Natriuretic Peptide (BNP); Myoglobin; Other Biomarkers2) By Product: Reagent; Instrument; Chemiluminescence; Immunofluorescence; Immunochromatography; ELISA
3) By Indication: Myocardial Infarction; Congestive Heart Failure; Acute Coronary Syndrome; Other Indications
4) By End User: Laboratory Testing Facilities; Hospital Labs; Reference Labs; Contract Testing Labs; Point-Of-Care Testing Facilities; Academic Institutions
Subsegments:
1) By Troponin: Troponin I; Troponin T; Troponin Diagnostic Kits2) By Creatine Kinase-MB (CK-MB): CK-MB Test Kits; CK-MB Diagnostic Panels
3) By B-Type Natriuretic Peptide (BNP): BNP Test Kits; NT-ProBNP Test Kits; BNP Diagnostic Panels
4) By Myoglobin: Myoglobin Test Kits; Myoglobin Diagnostic Panels
5) By Other Biomarkers: Ischemia Modified Albumin (IMA); Heart Fatty Acid Binding Protein (HFABP); C-Reactive Protein (CRP)
Companies Mentioned: Abbott Laboratories; F Hoffmann-La Roche AG; Siemens Healthineers AG; Danaher Corporation; Thermo Fisher Scientific Inc; bioMérieux SA; Bio-Rad Laboratories Inc; Beckman Coulter Inc; QuidelOrtho Corporation; Randox Laboratories Ltd; DiaSorin SpA; Tosoh Corporation; PerkinElmer Inc; Sysmex Corporation; Mindray Bio-Medical Electronics Co Ltd; Lepu Medical Technology Beijing Co Ltd; Trinity Biotech plc; Fujirebio Holdings Inc; Euroimmun AG; Abcam plc; Creative Diagnostics
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cardiac Marker market report include:- Abbott Laboratories
- F Hoffmann-La Roche AG
- Siemens Healthineers AG
- Danaher Corporation
- Thermo Fisher Scientific Inc
- bioMérieux SA
- Bio-Rad Laboratories Inc
- Beckman Coulter Inc
- QuidelOrtho Corporation
- Randox Laboratories Ltd
- DiaSorin SpA
- Tosoh Corporation
- PerkinElmer Inc
- Sysmex Corporation
- Mindray Bio-Medical Electronics Co Ltd
- Lepu Medical Technology Beijing Co Ltd
- Trinity Biotech plc
- Fujirebio Holdings Inc
- Euroimmun AG
- Abcam plc
- Creative Diagnostics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 13.95 Billion |
| Forecasted Market Value ( USD | $ 22.7 Billion |
| Compound Annual Growth Rate | 12.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
